1. Home
  2. SKE vs CRNX Comparison

SKE vs CRNX Comparison

Compare SKE & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skeena Resources Limited

SKE

Skeena Resources Limited

HOLD

Current Price

$29.23

Market Cap

3.8B

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$38.78

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKE
CRNX
Founded
1979
2008
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.9B
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
SKE
CRNX
Price
$29.23
$38.78
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$76.75
AVG Volume (30 Days)
587.9K
982.0K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,039,000.00
Revenue This Year
N/A
$720.10
Revenue Next Year
$37,573.35
$184.67
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.13
$25.83
52 Week High
$38.77
$57.99

Technical Indicators

Market Signals
Indicator
SKE
CRNX
Relative Strength Index (RSI) 40.10 50.04
Support Level $27.50 $33.19
Resistance Level $34.96 $45.32
Average True Range (ATR) 1.28 1.49
MACD -0.42 -0.02
Stochastic Oscillator 7.26 35.09

Price Performance

Historical Comparison
SKE
CRNX

About SKE Skeena Resources Limited

Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: